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Background: Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of
ovarian tumours. However, epidemiologic evidence on this topic is limited.
Methods:We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional
hazards models, we estimated associations between hyper- and hypothyroidism and medications prescribed for these conditions
with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.
Results: Overall, there was a nonsignificant association with history of hyperthyroidism (n¼ 160 cases) and mortality (HR¼ 1.22;
95% CI¼ 0.97–1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated
with an increased risk of death (HR¼ 1.94; 95% CI¼ 1.19–3.18). A more modest association was observed with history of
hypothyroidism (n¼ 624 cases) and mortality (HR¼ 1.16; 95% CI¼ 1.03–1.31). Neither duration of hypothyroidism nor use of
thyroid medications was associated with survival.
Conclusions: In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history
of hypothyroidism were associated with worse 5-year survival.
Ovarian cancer is the most deadly gynaecological cancer with 5-
year survival rate of B46% (Siegel et al, 2017). Some previous
epidemiologic studies have shown that hormonal factors, including
hormone therapy (HT) and cortisol, can impact mortality
(Rodriguez et al, 1995; Mascarenhas et al, 2006; Schrepf et al,
2015).
In addition to HT and cortisol, there is recent evidence that
exposure to thyroid hormones may also play a role in ovarian
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cancer progression. An in vitro study has demonstrated that 3,5,30-
triiodo-L-thyronine (T3) and L-thyroxine (T4) hormones at
physiological levels are able to initiate proliferation and improve
survival of ovarian cancer cells, whereas exposure to these
hormones at concentrations below normal serum levels may result
in slower growth of ovarian cancer cells (Shinderman-Maman et al,
2015). The results of the only epidemiologic study that assessed the
association between thyroid disease and ovarian cancer mortality
were suggestive of a possible link between hyperthyroidism and
mortality among these patients (Journy et al, 2017). However, the
study was based on a very small number of cases.
We evaluated associations between history of hyper- and
hypothyroidism and all-cause mortality using a large international
study of women diagnosed with ovarian cancer.
MATERIALS AND METHODS
We pooled data on history of hyper- and hypothyroidism from the
studies participating in the Ovarian Cancer Association Con-
sortium (OCAC). Of all the studies in OCAC, 11 included data on
history of hyperthyroidism and 10 on hypothyroidism. All
participants provided informed consent; and study protocols were
approved by the institutional review boards or ethics committees
for each study site. Characteristics of the studies included in this
pooled analysis are presented in Table 1. Although most of the data
were based on self-report, three studies (HJO, HOP, and LAX)
included data collected from medical records. Almost all the
studies, except for JPN, provided information on the age at
diagnosis with either of these diseases, and four studies (HJO, LAX,
NEC, and NJO) also collected information on use of medications
prescribed for these conditions including radioactive iodine, anti-
thyroid agents, and thyroid hormones.
Our final study population included patients diagnosed with
epithelial invasive ovarian, peritoneal, or fallopian tube cancers.
Among these women, 5198 had information on history of
hyperthyroidism and 5662 had information on history of
hypothyroid disease (yes/no). Hyperthyroidism was defined as
any hyperthyroid disease, including Grave’s disease, and hypothyr-
oidism as any hypothyroid disease, including Hashimoto’s disease.
An additional exposure of interest was time since being
diagnosed with these thyroid conditions before the date of
diagnosis of ovarian cancer. This was calculated by subtracting
age at the time of being diagnosed with either hyper- or
hypothyroid disease from the age of diagnosis with ovarian cancer.
We then dichotomised this variable using the 5 years as the
cutpoint. Another exposure of interest was the use of medications
prescribed for hyper- or hypothyroid disease, dichotomised as
yes/no. The outcome of interest was overall survival (OS) after
ovarian cancer diagnosis censored at 5 years of follow-up defined
as the time period between the date of diagnosis and the date of
death, date of last contact, or 5 years after the date of diagnosis,
whichever occurred first. Additional outcome of interest was
survival censored at 10 years of follow-up.
We used age-, stage-, and site-adjusted Cox proportional
hazards models to estimate associations between each of these
exposures and all-cause mortality by calculating hazard ratios
(HRs) and corresponding 95% confidence intervals (CIs). We also
adjusted the models for each of the descriptive and disease
characteristics indicated in Table 2. However, because such
adjustment did not change the age-, stage-, and site-adjusted
associations by 410%, none of these covariates were included in
the final models.
We assessed statistical heterogeneity between study-specific HRs
using I2 statistics and Cochran’s Q-statistics (Higgins et al, 2003).
No heterogeneity was observed, and therefore we estimated and
reported pooled HRs and 95% CIs.
Furthermore, we examined whether associations differed
between strata of histotype (serous vs non-serous), BMI
(18.5 kgm 2oBMIo25.0 kgm 2 vs BMI X25.0 kgm 2), age at
diagnosis (o65 vs X65 years), and stage of disease (local/regional
vs distant). Presence of multiplicative interaction was examined by
including cross-product terms between the exposures of interest
and potential effect modifiers (histotype, BMI, age at diagnosis,
and stage of disease) and utilising likelihood ratio tests to assess
significance of these terms. We additionally accounted for left
truncation in all the models to take into consideration time
between the date of ovarian cancer diagnosis and date of the
interview and the inability to enroll women who had died before
the recruitment date.
Finally, we conducted additional analyses after excluding
patients who reported history of both hyper- and hypothyroid
disease (n¼ 23). For medication use, we also conducted separate
analyses limited to patients with a corresponding thyroid disease.
All statistical tests used in the analyses were two sided; P-values
of o0.05 were considered significant.
RESULTS
Descriptive and clinical characteristics of the participants accord-
ing to thyroid disease status are presented in Table 2. Participants
diagnosed with hyperthyroidism or hypothyroidism were more
likely to be older and postmenopausal. Those with history of
hypothyroidism were also more likely to be white, obese, more
educated, and have a history of hysterectomy, and less likely to
breastfeed. Median follow-up times from ovarian cancer diagnosis
for patients with neither hypo- nor hyperthyroid disease, patients
with hyperthyroidism, and patients with hypothyroidism were
1791, 1574, and 1459 days, respectively.
We observed a positive association between history of
hyperthyroidism and overall mortality censored at 5 years of
follow-up in the overall sample of patients diagnosed with ovarian
cancer, although this association was not statistically significant
(HR¼ 1.22; 95% CI¼ 0.97–1.53; Table 3). In strata defined by time
since diagnosis, only hyperthyroid disease diagnosed within 5 years
of ovarian cancer diagnosis was associated with increased mortality
(HR¼ 1.94; 95% CI¼ 1.19–3.18). History of hypothyroidism was
associated with a slight increased risk of death (HR¼ 1.16; 95%
CI¼ 1.03–1.32). No association was observed between time since
diagnosis of hypothyroidism and mortality. For 10-year survival,
HRs were slightly attenuated and, for hypothyroidism and duration
of hyperthyroidism of 5 years or less before ovarian cancer
diagnosis, were no longer statistically significant.
Ever use of anti-hyper- or anti-hypothyroid medications was
also not associated with mortality (HR¼ 0.69; 95% CI¼ 0.17–2.80
and HR¼ 1.04; 95% CI¼ 0.77–1.40, respectively). The associations
were not modified by histotype, BMI, age at diagnosis of ovarian
cancer, or stage of disease. For medications, conducting analysis
among individuals with a corresponding thyroid disease did not
considerably influence the observed associations. Accounting for
left truncation did not considerably change the HRs observed in
the main analysis.
DISCUSSION
In this large study, we found that recent history of hyperthyroidism
and overall history of hypothyroidism were associated with
increased 5-year all-cause mortality among ovarian cancer patients.
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This increased mortality associated with hyperthyroidism may
be explained by the biological activity of thyroid hormones. One of
these hormones, T3, has been shown to promote expression of
genes associated with inflammation including cyclooxygenase-2
and matrix metalloproteinase-9 (Rae et al, 2007), both of which
can play a role in tumour invasion or angiogenesis (Lee et al, 2006;
Hu et al, 2012). In one preclinical study, both T3 and T4 inhibited
transcription of genes involved in tumour suppression, GDF-15
and IGFBP-6, and cell cycle, p21 and p16 (Shinderman-Maman
et al, 2015), thereby influencing proliferation and survival of
ovarian cancer cells. A recent increase in exposure to these
hormones may result in increased proliferation and invasiveness of
ovarian tumours and, consequently, impact survival of ovarian
cancer patients, possibly explaining the association observed in
our study.
Out of the four studies conducted to examine the link between
thyroid disease and ovarian cancer (Ness et al, 2000; Brinton et al,
2007; Kang et al, 2013), only one was conducted to assess the
association with survival (Journy et al, 2017). Similarly to us, the
authors of the survival study concluded that there was a suggestion
of the association between hyperthyroidism and mortality among
ovarian cancer patients (Journy et al, 2017). However, our study
was considerably larger; we were also able to control for important
prognostic factors.
We found that overall history of hypothyroidism was also
associated with a slightly increased mortality. This finding is
different from what we had expected based on the in vitro finding
that thyroid hormones below biologically normal levels slow
growth of ovarian cancer cells (Shinderman-Maman et al, 2015).
There are several possible explanations for our observation. One
treatment for hyperthyroidism is radioiodine therapy; this treat-
ment can result in transient or permanent hypothyroidism in
patients (Burch and Cooper, 2015). The observed decreased 5-year
survival that we found associated with hypothyroidism could be
the result of previous hyperthyroidism. In our study population,
however, exclusion of 23 patients with history of both hyper- and
hypothyroidism from the analysis did not change the observed
estimates.
Another possible explanation is that external thyroid hormones
prescribed for hypothyroidism might be in excess of what is
physiologically required or that treatment regimens do not
replicate normal secretion patterns. This excessive exposure to
Table 1. Characteristics of studies included in the analysis: Ovarian Cancer Association Consortiuma
Study acronym Study name
Study
location,
time of
enrolment
Data
collection
method
Median time of
follow-up, days
(range of
follow-up)
Determination of
history of hyper/
hypothyroidism
Patients with
hyperthyroid
disease,
N (%)
Patients with
hypothyroid
disease,
N (%)
AUS (Merritt et al, 2008) Australian Ovarian
Cancer Study
Australia,
Jan 2002 to Jun
2006
Self-completed
questionnaire
1705 (19-3672) Q: Ever having disease requiring
regular medical care
10 (0.9) 27 (2.3)
DOV (Rossing et al,
2007; Bodelon et al,
2012)
Disease of the Ovary and
their Evaluation Study
USA:
Washington,
2002–2005
(DOV)
2006–2009
(DVE)
In-person interview 1398 (243–3192) Q: Disease diagnosed by
physician or health care
professional before being
diagnosed with ovarian cancer
13 (2.6) 100 (16.7)
GER (Royar et al, 2001) German Ovarian Cancer
Study
Germany,
1993–1996
Self-administered
questionnaire
1464 (18–6060) Q: Ever having disease
diagnosed by physician
10 (4.4) 7 (3.1)
HAW (Goodman et al,
2008; Lurie et al, 2008)
Hawaii Ovarian Cancer
Study
USA:
Hawaii,
1993–2008
In-person interview 2750 (143–7662) Q: Disease diagnosed by
physician before being
diagnosed with ovarian cancer
22 (4.6) 25 (5.2)
HJO (Song et al, 2009) Hannover-Jena Ovarian
Cancer Study
Germany
2007–2011
MRR 707 (9–8722) MRR: reporting of disease 7 (5.4) 29 (19.1)
HOP (Lo-Ciganic et al,
2012)
Hormones and Ovarian
Cancer Prediction Study
USA:
Pennsylvania,
Ohio, and
New York,
2003–2009
In-person interview
and MRR
1821 (40–3982) Q: Disease diagnosed by
physician or health care
professional before being
diagnosed with ovarian cancer;
MRR: reporting of disease
25 (4.2) 109 (16.1)
JPN (Hamajima et al,
2001)
Hospital-based Research
Program at Aichi Cancer
Center
Japan,
2001–2005
In-person interview 1069 (43–3396) Q: Ever having disease 2 (3.1) 0
LAX Women’s Cancer
Program at the Samuel
Oschin Comprehensive
Cancer Institute
USA:
California,
1989 to present
MRR 1498 (13–8239) MRR: reporting of disease 3 (1.1) 56 (17.3)
NCO (Schildkraut et al,
2008, 2010)
North Carolina Ovarian
Cancer Study
USA:
North Carolina,
1999–2008
Self-completed
questionnaire
1836 (93–5730) Q: Disease diagnosed by
physician before being
diagnosed with ovarian cancer
32 (3.9) 133 (14.3)
NEC (Terry et al, 2005;
Merritt et al, 2013)
New England
Case-Control Study of
Ovarian Cancer
USA:
New Hampshire
and
Massachusetts,
1992–2003
In-person interview 2904 (70–7709) Q: Ever having disease before
being diagnosed with ovarian
cancer
25 (3.3) 97 (11.6)
NJO (Bandera et al,
2011; Chandran et al,
2011; Gifkins et al,
2012)
New Jersey Ovarian
Cancer Study
USA:
New Jersey,
2002–2008
Phone interview 2375 (165–4085) Q: Disease diagnosed by health
care professional before being
diagnosed with ovarian cancer
11 (5.4) 41 (17.7)
Abbreviations: MRR¼medical record review; Q¼question.
aJPN did not provide information on the age at being diagnosed with hyper- or hypothyroid disease; LAX did not provide information on the age at being diagnosed with hyperthyroidism; AUS
patients were not specifically asked about thyroid disease, and thyroid disease history was determined from the answers to the open-ended question on having other diseases; HJO, LAX, NEC
and NJO collected information on anti-hyper- and anti-hypothyroid medication intake.
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thyroid hormone, therefore, can result in activation of the
biological processes described above. We did not observe any
association between intake of thyroid hormones and survival.
However, it could be that duration and timing of thyroid hormone
intake are more important than the overall exposure to thyroid
hormones. Data on timing of thyroid hormone replacement were
not available to us; therefore, we were not able to explore these
associations further.
In interpreting of this study, understanding of the strengths and
weaknesses is critical. Important strengths include a large study
size allowing us to examine main effects as well as associations
within strata of potential effect modifiers. Because ovarian cancer is
relatively rare, pooled data such as these are critical for a more
detailed examination of factors related to survival. Limitations of
the study include reliance on self-report of hyper- and hypothyr-
oidism rather than medical reports or even actual measurement of
Table 2. Demographic and disease characteristics of ovarian cancer patients, Ovarian Cancer Association Consortiuma
Characteristics
No history of either
hyper- or
hypothyroidism,
N¼5038
History of
hyperthyroidism,
N¼160 P-valueb
History of
hypothyroidism,
N¼624 P-valueb
Age at diagnosis with ovarian cancer,
mean (s.d.)
56.8 (11.4) 61.6 (9.1) o0.001 60.1 (9.7) o0.001
Race, N (%)
White 4260 (85.2) 131 (81.9) 0.24 580 (93.5) o0.001
Non-white 737 (14.8) 29 (18.1) 40 (6.5)
BMI, kgm2
18.5–24.9 2058 (44.6) 72 (48.6) 0.58 204 (35.2) o0.001
25 to p30 1353 (29.3) 42 (28.4) 168 (29.0)
X30 1202 (26.1) 34 (23.0) 207 (35.8)
Education, N (%)
High school or less 2078 (42.8) 73 (48.3) 0.18 194 (32.6) o0.001
More than high school 2773 (57.2) 78 (51.6) 401 (67.4)
Family history of breast or ovarian
cancer, N (%)
No 1180 (23.4) 37 (23.1) 0.58 140 (22.4) 0.27
Yes 1008 (20.0) 27 (16.9) 142 (22.8)
Unknown/missing 2850 (56.6) 96 (60.0) 342 (54.8)
Menopausal status, N (%)
Premenopausal 1480 (30.1) 25 (16.0) o0.001 122 (20.2) o0.001
Postmenopausal 3438 (69.9) 131 (84.0) 483 (79.8)
Ever breastfed, N (%)
Never pregnant 933 (19.8) 29 (19.2) 0.39 100 (17.9) 0.03
Pregnant but not breastfed 1719 (36.5) 63 (41.7) 236 (42.3)
Breastfed 2063 (43.7) 59 (39.1) 222 (39.8)
Hysterectomy, N (%)
No 3903 (82.0) 112 (77.8) 0.20 403 (71.7) o0.001
Yes 858 (18.0) 32 (22.2) 159 (28.3)
Pregnancy ever, N (%)
No 933 (18.9) 29 (18.5) 0.88 100 (16.8) 0.19
Yes 3993 (81.1) 128 (81.5) 497 (83.2)
Oral contraceptive use ever, N (%)
No 1951 (41.5) 75 (48.4) 0.09 210 (38.6) 0.19
Yes 2746 (58.5) 80 (51.6) 334 (61.4)
Tubal ligation, N (%)
No 3931 (81.3) 120 (77.9) 0.29 476 (80.3) 0.55
Yes 905 (18.7) 34 (22.1) 117 (19.7)
Stage, N (%)
Localised 819 (16.3) 23 (14.4) 0.18 91 (14.6) 0.10
Regional 904 (17.9) 38 (23.7) 99 (15.9)
Distant 3229 (64.1) 94 (59.7) 417 (66.8)
Unknown 86 (1.7) 5 (3.2) 17 (2.7)
Grade, N (%)
Well differentiated 535 (10.6) 13 (8.1) 0.19 56 (9.0) 0.25
Moderately differentiated 1086 (21.6) 28 (17.5) 133 (21.3)
Poorly differentiated 2765 (54.8) 89 (55.6) 339 (54.3)
Undifferentiated 301 (6.0) 14 (8.8) 50 (8.0)
Unknown 351 (7.0) 16 (10.0) 46 (7.4)
Histology, N (%)
Serous 3004 (59.6) 72 (45.0) 0.24 395 (63.3) 0.08
Non-serous 2034 (40.4) 88 (55.0) 229 (36.7)
Abbreviation: BMI¼body mass index.
aNumbers may not add up because of missing observations.
bP-value for w2 test for categorical variables and t-test for age at diagnosis variable; tests used to compare diseased and non-diseased patients.
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T3 and T4 hormones. Moreover, there is a possibility that
our finding can be explained by chance only or by the presence
of residual confounding because of our inability to control
for treatment after ovarian cancer diagnosis. Finally, the outcome
of interest was all-cause mortality instead of ovarian cancer-
specific mortality. However, as shown in other OCAC survival
studies, among these patients, most deaths are likely to be
attributable to ovarian cancer (Cannioto et al, 2016; Minlikeeva
et al, 2017).
Nonetheless, our findings potentially could have important
clinical implications in relation to prognosis of ovarian cancer
among women diagnosed with hyper- or hypothyroid diseases if
validated in other studies. Clinicians may need to be aware of the
fact that ovarian cancer patients with history of thyroid disease,
particularly hyperthyroidism, can experience worse prognosis
compared with patients without such history. It could also be
important to monitor and correct thyroid hormones levels at the
time of diagnosis with ovarian cancer.
Future studies need to confirm whether history of thyroid
disease influences survival outcomes among ovarian cancer
patients.
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